Maturitas

Climacteric symptoms in a representative Dutch population sample as measured with the Greene Climacteric Scale
pp. 123-128(6)
Authors: Barentsen R.; van de Weijer P.H.M.; van Gend S.; Foekema H.

Women at mid-life: symptoms, attitudes, and choices, an internet based survey
pp. 129-136(8)
Authors: Conboy L.; Domar A.; O'Connell E.

Effects of hormone replacement therapy on cognitive performance in elderly women
pp. 137-146(10)
Authors: Binder E.F.; Schechtman K.B.; Birge S.J.; Williams D.B.; Kohrt W.M.

Prognosis of breast cancers detected in women receiving hormone replacement therapy
pp. 147-156(10)
Authors: Delgado R.C.; Lubian Lopez D.M.

Course of primary headaches during hormone replacement therapy
pp. 157-163(7)
Authors: Nappi R.E.; Cagnacci A.; Granella F.; Piccinini F.; Polatti F.; Facchinetti F.

The effects of hormone replacement therapy on lipid peroxidation and antioxidant status
pp. 165-170(6)
Authors: Ozden S.; Dildar K.; Kadir Y.H.; Gulizar K.

Effects of short-term melatonin administration on lipoprotein metabolism in normolipidemic postmenopausal women
pp. 171-177(7)
Authors: Wakatsuki A.; Okatani Y.; Ikenoue N.; Kaneda C.; Fukaya T.

Detection of testosterone and estrogen receptors in the postmenopausal endometrium
pp. 179-188(10)
Authors: Maia H.; Maltez A.; Fahel P.; Athayde C.; Coutinho E.

Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch
pp. 189-196(8)
Authors: Jarvinen A.; Backstrom A.-C.; Elfstrom C.; Viitanen A.

17-Estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women
pp. 197-203(7)
Authors: Stevenson J.C.; Teter P.; Lees B.

Oral, water-soluble combined estrogen/calcium preparation for postmenopausal therapy
pp. 205-210(6)
Authors: Downey D.; Spencer S.J.; Deghenghi R.; Jaffe R.B.